Krystal Biotech, Inc.
KRYS
Updated: 22/09/2026, 23:39:02
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
No summaries found.
- Share price
- $350.88
- Market cap
- $10.34B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Krish S. Krishnan
- Employees
- 295
- IPO date
- 20/09/2017
- Beta
- 0.537
- Last dividend
- $0.00
- Day range
- $335.23 – $353.85
- 52-week range
- $158.08 – $382.54
- 1-day performance
- 5.10%
- 1-year performance
- 121.96%
- Current drawdown (1Y)
- -8.28%
- CIK
- 0001711279
- CUSIP
- 501147102
- ISIN
- US5011471027
- Created
- 07/12/2025, 04:59:42
- Last update
- 22/09/2026, 23:39:02
Track Krystal Biotech, Inc. with an AI analyst
See which prediction-market events move KRYS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
Zacks Investment Research • STOCK • 05/06/2026, 15:00:46
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
Zacks Investment Research • STOCK • 04/06/2026, 13:31:09
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Zacks Investment Research • STOCK • 26/05/2026, 12:51:11
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewsWire • STOCK • 18/05/2026, 10:00:00
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 18:40:58
This Profitable Biotech Stealthily Climbs Into A Buy Zone
Investors Business Daily • STOCK • 11/05/2026, 16:15:40
Krystal Biotech: Vyjuvek Is Not The Primary Asset
Seeking Alpha • STOCK • 10/05/2026, 08:10:56
Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027
Seeking Alpha • STOCK • 06/05/2026, 10:49:36
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
Zacks Investment Research • STOCK • 05/05/2026, 16:00:36
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
Zacks Investment Research • STOCK • 04/05/2026, 11:15:25
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks Investment Research • STOCK • 27/04/2026, 13:05:36
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
The Motley Fool • STOCK • 22/02/2026, 13:45:39